<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230008</url>
  </required_header>
  <id_info>
    <org_study_id>katty7</org_study_id>
    <secondary_id>katt7</secondary_id>
    <nct_id>NCT01230008</nct_id>
  </id_info>
  <brief_title>Radiotherapy in Primary Mediastinal Lymphoma</brief_title>
  <acronym>pml</acronym>
  <official_title>Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in
      diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy
      in patients treated with R-CHOP
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of progression free-survival and overall survival at &gt; 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess toxicity secondary to mediastinal radiotherapy</measure>
    <time_frame>&gt; 5 years</time_frame>
    <description>Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">198</enrollment>
  <condition>Adjuvant Radiotherapy on Complete Remission Patients</condition>
  <arm_group>
    <arm_group_label>Radiotherapy in mediastinal lymphoma</arm_group_label>
    <description>Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy in mediastinal lymphoma</arm_group_label>
    <description>Radiotherapy will no be administered in patients treated with R-CHOP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy in primary mediastinal lymphoma</arm_group_label>
    <description>Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>no drugs</intervention_name>
    <description>Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP</description>
    <arm_group_label>Radiotherapy in primary mediastinal lymphoma</arm_group_label>
    <other_name>no applicable</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary mediastinal lymphoma treated in an tertiary medical center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of primary mediastinal lymphoma No previous treatment performance status &lt; 2 HIV,
        Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function

        Exclusion Criteria:

        pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncology Research Unit</name>
      <address>
        <city>MÃ¨xico DF</city>
        <state>DF</state>
        <zip>06725</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2010</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Agustin Aviles</name_title>
    <organization>Mexican Institute of Social Security</organization>
  </responsible_party>
  <keyword>primary mediastinal lymphoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

